Portal de Periódicos da CAPES

Advances in Our Understanding of the Mechanisms of the Neurotoxicity of MPTP and Related Compounds

1993; Wiley; Volume: 61; Issue: 4 Linguagem: Inglês

10.1111/j.1471-4159.1993.tb13610.x

1471-4159

Keith F. Tipton, Thomas P. Singer,

Neurological disorders and treatments

Journal of NeurochemistryVolume 61, Issue 4 p. 1191-1206 Advances in Our Understanding of the Mechanisms of the Neurotoxicity of MPTP and Related Compounds Keith F. Tipton, Keith F. Tipton Department of Biochemistry, Trinity College, Dublin, IrelandSearch for more papers by this authorThomas P. Singer, Corresponding Author Thomas P. Singer Department of Biochemistry and Biophysics and Division of Toxicology, University of California, and Molecular Biology Division, Department of Veterans Affairs Medical Center, San Francisco, California, U.S.A.Address correspondence and reprint requests to Dr. T. P. Singer at Department of Biochemistry and Biophysics, Molecular Biology Division, Department of Veterans Affairs Medical Center, 4150 Clement Street, 151-S, San Francisco, CA 94121. U.S.A.Search for more papers by this author Keith F. Tipton, Keith F. Tipton Department of Biochemistry, Trinity College, Dublin, IrelandSearch for more papers by this authorThomas P. Singer, Corresponding Author Thomas P. Singer Department of Biochemistry and Biophysics and Division of Toxicology, University of California, and Molecular Biology Division, Department of Veterans Affairs Medical Center, San Francisco, California, U.S.A.Address correspondence and reprint requests to Dr. T. P. Singer at Department of Biochemistry and Biophysics, Molecular Biology Division, Department of Veterans Affairs Medical Center, 4150 Clement Street, 151-S, San Francisco, CA 94121. U.S.A.Search for more papers by this author First published: October 1993 https://doi.org/10.1111/j.1471-4159.1993.tb13610.xCitations: 411Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL REFERENCES Adams J. D. and Odunze I. N. (1991) Biochemical mechanisms of 1-methyl-4-phenyl-1, 2, 3.6-tetrahydropyridine toxicity: could oxidative stress be involved in the brain Biochem. Pharmacol. 41, 1099– 1105. Aiuchi T., Shirane Y., Kinemuchi H., Arai Y., Nakaya K., and Nakamura Y. (1988) Enhancement by tetraphenylboron of inhibition of mitochondrial respiration induced by 1-methyl-4-phenylpyridinium ion (MPP+). Neurochem. Int. 12, 525– 531. Aiuchi T., Syou M. Matsunaga M., Kinemuchi H., Nakaya K., and Nakamura Y. (1992) Enhancement of the uptake of 1-methyl-4-phenylpyridinium ion (MPP+) in mitochondria by tetraphenylboron. Biochim. Biophys. Acta 1103, 233– 238. Ansher S. S. Cadet J. L., Jakob W. B. and Baker J. K. (1986) Role of N-methyltransferases in the neurotoxicity associated with the metabolism of MPTP and other 4-substituted pyridines present in the environment. Biochem. Pharmacol. 35, 3359– 3363. Arai Y., Kinemuchi H., Hamamichi N., Satoh N., Tadano T., and Kisara K. (1986) Inhibition of rat brain monoamine oxidase by some analogs of 1-methyl-4-phenyl-1, 2, 3.6-tetrahydropyridine and 1-methyl-4-phenylpyridinium ion. Neurosci. Lett. 66, 43– 48. Baker J. R., Bourne R. F. Davis W. M. and Waters I. W. (1984) Metabolism of 1-methyl-4-phenyl-1, 2, 3,6-tetrahydropyridine (MPTP) in mouse liver preparations. Biochem. Biophvs. Res. Commun. 125, 484– 490. Barbeau A., Poirier J., Dallaire L., Rucinka E., Buu N. T., and Donaldson J. (1986) Studies on MPTP, MPP+ and paraquat in frogs and in vitro, in MPTP: A Neurotoxin Producing a Parkinsonian Syndrome ( S. P. Markey, N. Castagnoli, A. J. Trevor, and I. J. Kopin, eds), pp. 85– 103. Academic Press, New York . Birkmayer W., Riederer P. Ambrozi L., and Youdim M. B. H. (1977) Implications of combined treatment with "Mardopar" and L-deprenyl in Parkinson's disease. A long term therapy. Lancet i, 439– 443. Birkmayer W., Knoll J., Riederer P., Youdim M. B. H., Nhars V., and Marton J. (1985) Increased life expectancy resulting from addition of L-deprenyl to Mardopar treatment in Parkinson's disease: a longterm study. J. Neural Transm. 64, 113– 127. Booth R. G., Castagnoli N., and Rollema H. (1989) Intracerebral microdialysis neurotoxicity studies of quinoline and isoquinoline derivatives related to MPTP/MPP+. Neurosci. Lett. 100, 306– 312. Bradbury A. J., Costall B., Domeney A. M., Testa B., Jenner P., Marsden C. D., and Naylor R. J. (1985) The toxic actions of MPTP and its metabolite MPP+ are not mimicked by analogues of MPTP lacking the 1-methyl moiety. Neurosci. Lett. 61, 121– 126. Buckman T. D. (1991) Toxicity of MPTP and structural analogs in clonal cell lines of neuronal origin expressing B type monoamine oxidase activity. Mol. Chem. Neuropathol. 15, 87– 102. Calne D. B., Langston J. W., Martin W. R. R., Stroessl A. J. Ruth T. J., Adam M. J., Pate B. D., and Schulzer M. (1985) Positron emission tomography after MPTP: observations relating to the cause of Parkinson's disease. Nature 317, 246– 248. Chiueh C. C. Johannessen J. N. Sun J. L., Bacon J. P., and Markey S. P. (1986) Reversible neurotoxicity of MPTP in the nigrostriatal dopaminergic system in mice, in MPTP: A Neurotoxin Producing a Parkinsonian Syndrome ( S. P. Markey, N. Castagnoli, A. J. Trevor, and I. J. Kopin, eds), pp. 473– 479. Academic Press, New York . Chiueh C. C., Huang S. J., and Murphy D. L. (1992) Enhanced hydroxyl radical generation by 2′-methyl analog of MPTP: suppression by clorgyline and deprenyl. Synapse 11, 346– 348. Chiueh C. C., Huang S. J., and Murphy D. L. (1993) Suppression of hydroxyl radical formation by MAO inhibitors: a novel neuroprotective mechanism in dopaminergic neurotoxicity. J. Neural Transm. (in press). Cleeter M. W. J., Cooper J. M., and Schapira A. H. V. (1992) Irreversible inhibition of mitochondrial complex I by 1-methyl-4-phenylpyridinium (MPP+): evidence for free radical involvement. J. Neurochem. 58, 786– 789. Collins M. A., Matsubara K., and Neafsey E. J. (1993) Carboline bioactivation (N-methylation) and Parkinson's disease. Neurochem. Res. (in press). Corongiu F. P., Dessi M. A., Banni S., Bernardi F., Piccardi M. P., Del Zompo M., and Corsini G. U. (1987) MPTP fails to induce lipid peroxidation in vivo. Biochem Pharmacol. 36, 2251– 2253. D'Amato R. J., Lipman Z. P., and Snyder S. H. (1986) Selectivity of the parkinsonian neurotoxin MPTP: toxic metabolite MPP+binds to neuromelanin. Science 231, 987– 989. Daniels A. J., Reinhard J. F., and Painter G. R. (1988a) Accumulation of 1-methyl-4-phenylpyridinine (MPP+) into bovine chromaffin granules results in a large restriction of molecular motion. A 13C and 31P NMR study. Biochem. Biophys. Res. Commun. 156, 1243– 1249. Daniels A. J., Reinhard J. F., and Painter G. R. (1988b) Energy-driven uptake of the neurotoxin 1-methyl-4-phenylpyridinium into chromaffin granules via the catecholamine transporter. J. Biol. Chem. 263, 5034– 5036. Davey G., Tipton K. F., and Murphy M. P. (1992) Uptake and accumulation of MPP* by rat liver mitochondria measured using an ion-selective electrode. Biochem. J. 288, 439– 443. Davey G., Tipton K. F., and Murphy M. P. (1993) Use of an electrode selective for 1-methyl-4-phenylpyridinium (MPP+) to measure its uptake and accumulation by mitochondria. J. Neural Transm. (in press). Dexter D. T., Carter C. J., Wells F. R., Lees A. J., Agid F., Agid Y., Jenner P., and Marsden C. D. (1989a) Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease. J. Neurochem. 52, 381– 389. Dexter D. T., Wells F. R., Lees A. J. Agid F., Agid Y., Jenner P., and Marsden C. D. (1989b) Increased nigral iron content and alterations of other metal ions occurring in brain in Parkinson's disease. J. Neurochem. 52, 1830– 1836. Donaldson J., McGreggor D., and La Bella F. (1982) Manganese neurotoxicity: a model for free radical mediated neurodegeneration Can. J. Pharmacol. 107, 1398– 1405. Dudley M. W. (1988) The depletion of rat cortical norepinephrine and the inhibition of [3H]norepinephrine uptake by xylamine does not require monoamine oxidase activity. Life Sci. 43, 1871– 1877. Ebmeier K. P., Mutch W. J., Calder S. A., Crawford J. R., Stewart L., and Besson J. O. A. (1989) Does idiopathic parkinsonism in Aberdeen follow intrauterine influenza J. Neurol. Neurosurg. Psychiatry 52, 911– 913. Elizan T. S., Casals J., and Swash M. (1989) No viral antigens detected in brain tissue from a case of acute encephalitis lethargica and another case of postencephalitic parkinsonism. J. Neurol. Neurosurg. Psychiatry 52, 800– 801. Fields J. Z., Albores R. R., Neafsey E. J., and Collins M. A. (1992) Inhibition of mitochondrial succinate oxidation—similarities and differences between N-methylated β-carbolines and MPP. Arch. Biochem. Biophys. 249, 539– 543. Finnegan K. T., Skratt J. J., Irwin I., Delanney L. E., and Langston J. W. (1990) Protection against DSP-4-induced neurotoxicity by deprenyl is not related to inhibition of MAO-B. Eur. J. Pharmacol 184, 119– 126. Forno L. S. Langston J. W., Delanney L. E., Irwin I., and Ricaurtc G. A. (1986) Locus coeruleus lesions and inclusions in MPTP-treated monkeys. Ann. Neurol. 20, 449– 455. Forno L. S., Langston J. W., Delanney L. E., and Irwin I. (1988) An electron microscope study of MPTP-induced inclusion bodies in an old monkey. Brain. Res. 448, 150– 157. Fowler C. J., Wiberg A. Oreland L., Marcusson J., and Winblad B. (1980) The effects of age on the activity and molecular properties of human brain monoamine oxidase. J. Neural Transm. 49, 1– 20. Freisleben H.-J., Lehr F., and Fuchs J. (1993) Lifespan of immuno-suppressed NMRI-mice is increased by deprenyl. J. Neural Transm. (in press). Fries D. S., de Vries J., Hazelhoff B., and Horn A. S. (1986) Synthesis and toxicity towards nigrostriatal dopamine neurons of 1-methyl-4-phenyl-1.2,3,6-tetrahydropyridine (MPTP) analogs. J. Med. Chem. 29, 424– 427. Fuller R. W. and Hemrick-Luecke S. K. (1987) Oral versus parenteral efficacy of 1-methyl-4-phenyl-l,2.3,6-tetrahydropyridine (MPTP): differential effects on depletion of heart norepinephrine and of striatal dopamine in mice. Biochem. Pharmacol. 36, 789– 792. Gibb C., Willoughby J. Glover V. Sandler M. Testa P., Jenner P., and Marsden C. D. (1987) Analogues of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine as monoamine oxidase substrates: a second ring is not necessary. Neurosci. Lett. 76, 316– 322. Gibbs W. R. G. and Lees A. J. (1991) Anatomy, pigmentation, ventral and dorsal subpopulations of the substantia nigra, and differential cell death in Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 54, 388– 396. Golbe L. I., Miller D. C., and Duvoisin R. C. (1990) Autosomal dominant Lewy-body Parkinson's disease. Adv. Neurol. 53, 287– 292. Hadjiconstantinou M., Xu J., Cavalla D., Laird H. E., and Neff N. H. (1986) The neurotoxicity of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine may have a cholinergic component, in MPTP: A Neurotoxin Producing a Parkinsonian Syndrome ( S. P. Markey, N. Castagnoli, A. J. Trevor, and I. J. Kopin, eds), pp. 481– 485. Academic Press, New York . Halliwell B. (1989) Oxidants and the central nervous system: some fundamental questions—is oxidative damage relevant to Parkinson's disease, Alzheimer's disease, traumatic injury or stroke Acta Neurol. Scand. 126, 23– 33. Hasegawa E., Takeshiga K., Oishi T., Murai Y., and Minikami S. (1990) 1-methyl-4-phenylpyridinium (MPP+) induces NADH-dependent superoxide formation and enhances NADH-dependent lipid peroxidation in bovine heart submitochondrial particles. Biochem. Biophys. Res. Commun. 170, 1049– 1055. Heikkila R. E., Nicklas W. J., Vyas I., and Duvoisin R. C. (1985) Dopaminergic toxicity of rotenone and the 1-methyl-4-phenyl-pyridinium ion after their stereotaxic administration to rats: implications for the mechanism of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity. Neurosci. Lett. 62, 389– 394. Heikkila R. E., Kindt M. V., Sonsalla P. K., Giovanni A., Youngster S. K., McKeown K. A., and Singer T. P. (1988) The importance of MAO-A in the bioactivation of neurotoxic MPTP analogs. Proc. Natl. Acad. Sci. USA 85, 6172– 6176. Heikkila R. E., Hwang J., Ofori S., Geller H. M., and Nicklas W. J. (1990) Potentiation by the tetraphenylboron ion of the effects of 1-methyl-4-phenyl- 1,2,3,6-tetrahydropyridine and its pyridinium metabolite. J. Neurochem. 54, 743– 750. Hirsch E. C., Graybiel A. M., and Agid Y. (1988) Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease. Nature 334, 345– 348. Hirsch E. C., Brandel J.-P., Galle P., Javoy-Agid F., and Agid Y. (1991) Iron and aluminum increase in substantia nigra of patients with Parkinson's disease: an x-ray microanalysis. J. Neurochem. 56, 446– 451. Ikebe S., Tanaka M., Ohno K., Suto W., Hanori K., Kondo T., Mizuno Y., and Ozawa T. (1990) Increase in deleted mitochondrial DNA in the striatum in Parkinson's disease and senescence. Biochem. Biophys. Res. Commun. 170, 1044– 1048. Irwin I. J., Langston J. W., and Delanney L. E. (1987) 4-Phenylpyridine (4PP): the relationship between striatal MPP+ concentration and neurotoxicity. Life Sci. 40, 731– 740. Irwin I. J., Ricaurte G. A., Delanney L. E., and Langston J. W. (1988) The sensitivity of nigrostriatal neurons to MPP+ does not increase with age. Neurosci. Lett. 87, 51– 56. Javitch J. A., D'Amato R. J., Strittmater S. M., and Snyder S. H. (1985) Parkinsonism-inducing neurotoxin. N-methyl-phenyl-1,2,3,6-tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity. Proc. Natl. Acad. Sci. USA 82, 2173– 2177. Jenner P. (1991) Relevance of MPTP neurotoxicity to Parkinson's disease, in Probes for Neurochemical Target Sites ( K. F. Tipton and L. L. Iversen, eds), pp. 73– 90. Royal Irish Academy, Dublin . Johannessen J. N., Chiueh C. C., Burns R. S., and Markey S. P. (1985) Differences in the metabolism of MPTP in the rodent and primate parallel differences in sensitivity to its neurotoxic effect. Life Sci. 36, 219– 224. Johannessen J. N., Chiueh C. C., Bacon J. P., Garrick N. A., Burns R. S., Weise V. K., Kopin I. J., Parisi J. E., and Markey S. P. (1989) Effects of 1-methyl-4-phenyl- 1,2,3,6-tetrahydropyridine in the dog: effect of pargyline pretreatment. J. Neurochem. 53, 582– 589. Kalaria R. N., Mitchell M. J., and Harik S. I. (1987) Correlation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity with blood-brain barrier monoamine oxidase activity. Proc. Natl. Acad. Sci. USA 84, 3521– 3535. Keller H. H. and Da Prada M. (1985) Evidence for the release of 1-methyl-4-phenylpyridinium ion (MPP+) from rat striatal neurons in vitro. Eur. J. Pharmacol. 119, 247– 250. Kinemuchi H., Fowler C. J., and Tipton K. F. (1987) The neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and its relevance to Parkinson's disease. Neurochem. Int. 11, 359– 373. Knoll J. (1988) The striatal dopamine dependency of life span in male rats. Longevity study with (-)-deprenyl. Mech. Ageing Dev. 46, 237– 262. Knoll J. (1989) The pharmacology of selegiline (l-deprenyl). New aspects. Acta Neurol. Scand. 126, 23– 33. Kohno M., Ohta S., and Hirobe M. (1986) Tetrahydroisoquinoline and 1-methyltetrahydroisoquinoline as novel endogenous amines in rat brain. Biochem. Biophys. Res. Commun. 140, 448– 454. Koike K., Takayanagi I., Wani S., Yanagita T., Ohta S., and Hirobe M. (1989) Effect of tetrahydroisoquinoline (TIQ), one of the endogenous substances inducing parkinsonism, on isolated rat deferens. Gen. Pharmacol. 20, 259– 260. Koller W. C., Wong G. F., and Lang A. (1989) Posttraumatic movement disorders: a review. Mov. Disord. 4, 20– 36. Krueger M. J., McKeown K., Ramsay R. R., Youngster S., and Singer T. P. (1990) Mechanism-based inactivation of monoamine oxidase A and B by tetrahydropyridines and dihydropyridines. Biochem. J. 268, 219– 224. Krueger M. J., Tan A. K., Ackrell B. A. C., and Singer T. P. (1993) Is complex II involved in the inhibition of mitochondrial respiration by MPP+ and N-methyl-β-carbolines Biochem. J. 291, 673– 676. Lambert C. E. and Bondy S. C. (1989) Effects of MPTP, MPP+ and paraquat on mitochondrial potential and oxidative stress. Life Sci. 44, 1277– 1284. Lange K. W. (1990) Age-dependent effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the rat. Adv. Behav. Biol. 38A, 593– 596. Langston J. W. (1985) Mechanisms of MPTP toxicity: more answers, more questions. Trends Pharmacol. Sci. 6, 375– 378. Lestienne P., Nelson I., Riederer P., Jellinger K., and Reichmann H. (1990) Normal mitochondrial genome in brain from patients with Parkinson's disease and complex I defect. J. Neurochem. 55, 1810– 1812. Lestienne P., Riederer P., and Jellinger K. (1991) Mitochondrial DNA in postmortem brain from patients with Parkinson's disease. J. Neurochem. 56, 1819. Liu Y., Peter D., Roghani A., Schuldiner S., Privé G. G., Eisenberg D., Brecha N., and Edwards R. H. (1992) A cDNA clone that suppresses MPP toxicity encodes a vesicular amine transporter. Cell 70, 539– 551. Makino Y., Tasaki Y., Ohta S., Tachikawa O., Kashiwasake M., and Hirobe M. (1990a) A novel neurotoxic tetrahydroisoquinoline derivative in vivo: formation of 1,3-dimethyl-1,2,3,4-tet-rahydroisoquinoline, a condensation product of amphetamines in brains of rats under chronic ethanol treatment. J. Neurochem. 55, 963– 969. Makino Y., Tasaki Y., Ohta S., and Hirobe M. (1990b) Confirmation of the enantiomers of 1-methyl-1.2,3,4-tetrahydroisoquinoline in mouse brain and foods applying gas chromatography/mass spectrometry with negative ion chemical ionization. Biomed. Environ. Mass Spectrom. 19, 415– 419. Makowski E. C. and Ordonez L. A. (1981) Behavioural alterations caused by formaldehyde-derived tetrahydroisoquinolines. Pharmacol. Biochem. Behav. 14, 639– 643. Marini A. M., Lipsky R. H., Schwartz J. P., and Kopin I. J. (1992) Accumulation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in cultured cerebellar astrocytes. J. Newochem. 58, 1250– 1258. Marsden C. D. (1987) Parkinson's disease in twins. J. Neurol. Neurosurg. Psychiatry 50, 105– 106. McCrodden J. M. Tipton K. F. and Sullivan J. P. (1990) The neurotoxicity of MPTP and the relevance to Parkinson's disease. Pharmacol. Toxicol. 67, 8– 13. Melamed E. Rosenthal J., and Youdim M. B. H. (1991) Immunity of fetal mice to prenatal administration of the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2.3.6-tetrahvdropyndine. J. Neurochem. 56, 1427– 1431. Mitchell I. J., Cross A. J. Sambrook M. A., and Crossman A. R. (1985) Sites of the neurotoxic action of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the macaque monkey include the ventral tegmental area and the locus coeruleus. Neurosci. Lett. 61, 195– 200. Mizuno Y. Ohta S. and Tanaka M. (1989) Deficiencies of complex I of the respiratory chain in Parkinson's disease. Biochem. Biophys. Res. Comimm. 163, 1450– 1455. Mizuno Y., Suzuki K., and Ohta S. (1990) Postmortem changes in mitochondrial respiratory enzymes in brain and preliminary observations in Parkinson's disease. J. Neurol. Sci. 96, 49– 57. Nagatsu T. (1987) MPTP and its relevance to Parkinson's disease. Neiirochem. Int. 11, 375– 377. Nagatsu T. and Yoshida M. (1988) An endogenous substance of the brain, tetrahydroisoquinoline, produces parkinsonism in primates with decreased dopamine, tyrosine hydroxylase and biopterin in the nigrostriatal regions. Neurosci. Lett. 87, 178– 182. Naoi M. Matsuura S., Parvez H. Takahashi T. Hirata Y., Minami M., and Nagatsu T. (1989) Oxidationof N-methyl-1.2.3,4-tetrahydroisoquinoline into the N-methyl-isoquinolinium ion by monoamine oxidase. J. Neurochem. 52, 653– 655. Naoi M., Maruyama W., Niwa T., and Nagatsu T. (1993) Novel toxins and Parkinson's disease. J. Neural Transm. (in press). O'Carroll A.-M., Tipton K. F. Sullivan J. P. Fowler C. J., and Ross S. B. (1987) Intra- and extra-synaptosomal deamination of dopamine and noradrenaline by the two forms of human brain monoamine oxidase. Implications for the neurotoxicity of N-methyl-4-phenyl-1,2.3.6-tetrahydropyridine in man. Biogenic Amines 4, 165– 178. Ochi N., Naoi M., Mogi M., Ohya Y., Mizutani N., Watanabe K., and Nagatsu T. (1990) The effects of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) administration to maternal mice on the catecholamine system in the brain of postnatal mice. Adv. Behav. Biol. 38A, 267– 270. Ohta S., Kohno M., Makino Y., Tachikawa O., and Hirobe M. (1987) Tetrahydroisoquinoline and 1-methyl-tetrahydroisoquinoline are present in human brain: relation to Parkinson's disease. Biomed. Res 8, 453– 456. Ottoboni S. Caldera P. Trevor A., and Castagnoli N. (1989) Deuterium isotope effect measurements on the interactions of the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine with monoamine oxidase B. J. Biol. Chem. 264, 13684– 13688. Parker W. D., Boyson S. J., and Parks J. K. (1989) Abnormalities of the electron transport chain in idiopathic Parkinson's disease. Ann. Neurol. 26, 719– 733. Parkinson Study Group (1989) Effect of deprenyl on the progression of disability in early Parkinson's disease. N. Engl. J. Med. 321, 1364– 1371. Perry T. L., Young V. W., Clavier R. M. Jones K. Wright J. M., Foulkes J. G., and Wall R. A. (1985) Partial protection from the dopaminergic neurotoxin N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine by four different antioxidants in the mouse. Neurosci. Lett. 60, 109– 114. Perry T. L., Hansen S., and Jones K. (1987) Exposure to cigarette smoke does not decrease the neurotoxicity of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice. Neurosci. Lett. 74, 217– 220. Poskanzer D. C. and Schwab R. S. (1961) Studies on the epidemiology of Parkinson's disease predicting its disappearance as a major entity by 1980. Trans. Am. Neurol. Assoc. 86, 234– 235. Rajput A. H., Uitti R. J. Stern W. Laverty W. O'Donnell K. O'Donnell D., Yuen W. K. and Dua A. (1987) Geography. drinking water chemistry, pesticides and herbicides in the etiology of Parkinson's disease. Can. J. Neurol. Sci. 13, 312– 316. Ramsay R. R. and Singer T. P. (1986) Energy-dependent uptake of N-methyl-4-phenyl-pyridinium, the neurotoxic metabolite of 1 -methyl-4-phenyl-1.2.3.6-tetrahvdropvridine. by mitochondria. J. Biol. Chem. 261, 7585– 7587. Ramsay R. R. and Singer T. P. (1992) Correlations between inhibition of NADH-Q oxidoreductase and oxyradical formation. Biochem. Biophys. Res. Commun. 189, 47– 52. Ramsay R. R., Mehlhorn R. J., and Singer T. P. (1989a) Enhancement by tetraphenylboron of the interaction of the 1-methyl-4-phenyl-pyridinium ion (MPP+) with mitochondria. Biochem. Biophys. Res. Commun. 159, 983– 990. Ramsay R. R. Youngster S. K., Nicklas W. J., McKeown K. A. Jin Y.-Z. Heikkila R. E., and Singer T. P. (1989b) Structural dependence of the inhibition of mitochondrial respiration and of NADH oxidase by 1-methyl-4-phenylpyridinium (MPP+)analogs and their energized accumulation by mitochondria. Proc. Natl. Acad. Sci. USA 86, 9168– 9172. Ramsay R. R. Krueger M. J. Youngster S. K., and Singer T. P. (1991a) Evidence that the inhibition sites of the neurotoxic amine 1-methyl-4-phenylpyridinium (MPP+) and the respiratory chain inhibitor, piericidin A, are the same. Biochem. J. 273, 481– 484. Ramsay R. R., Krueger M. J., Youngster S. K. G. Iuck M. R. Casida J. E., and Singer T. P. (1991b) Interaction of 1-methyl-4-phenylpyridinium ion (MPP+) and its analogs with the rotenone/piericidin binding site of NADH dehydrogenase. J. Neurochem. 56, 1184– 1190. Reinhard J. F. Diliberto E. J. Viveros O. H. and Daniels A. J. (1987) Subcellular compartmentation of 1-methyl-4-phenyl-pyridinium with catecholamines in adrenal medullary chromaffin vesicles may explain the lack of toxicity to adrenal chromaffin cells. Proc. Natl. Acad. Set. USA 84, 8160– 8164. Reynolds G. P. Ellsworth J. D., Blau K. Sandler M., Lees A. J. and Stern G. M. (1978) Deprenyl is metabolized to methamphetamine and amphetamine in man. Br. J Clin. Pharmacol. 6, 542– 544. Riachi N. J., Harik S. I., Kalaria R. N. and Sayre L. M. (1988) Onthe mechanism underlying l-mcthyl-4-phenyl-1.2.3.6-tetrahy-dropyridine neurotoxicity. II. Susceptibility among mammalian species correlates with the toxin's metabolic patterns in brain microvessels and liver. J. Pharmacol. Exp. Ther. 244, 443– 448. Riachi N. J. LaManna J. C. and Hank S. I. (1989) Entry of 1-methyl-4-phcnyl-1.2,3.6-tetrahydropyridine into the rat brain. J. Pharmacol. Exp Ther 249, 744– 748. Ricaurte G. A., Dclanney L. E., Irwin I. and Langston J. W. (1987) Older dopaminergic neurons do not recover from the effects of MPTP. Neuropharmacology 26, 97– 99. Rose S., Nomoto M. Kelly F. Kilpatrick G., Jenner P. and Marsden C. D. (1989) Increased caudate dopamine turnover may contribute to the recovery of motor functions in marmosets treated with the dopaminergic neurotoxin MPTP. Neurosci. Lett. 101, 305– 310. Rossetti Z. L. Sotgiu A., Sharp D. E., Hadjiconstantinou M., and Neff N. H. (1988) 1-methyl-4-phenyl-1.2.3,6-tctrahydropyridine (MPTP) and free radicals in vitro. Biochem. Pharmacol. 37, 4573– 4574. Saitoh T. Nijima K. and Mizuno Y. (1987) Long term effect of 1-methyl-4-phenyl-1,2.3.6-tetrahydropyridine (MPTP) on striatal dopamine content in voung and mature mice. J. Neurol. Sci. 77, 229– 235. Salo P. T. and Tatton W. G. (1991) Deprenyl reduces death of motorneurons caused by axotomy. J. Neurosci. Res. 31, 1– 7. Sanchez-Ramos J., Barrett J. N., Goldstein M., Weiner W. J., and Hefti F. (1986) 1-methyl-4-phenylpyridinium (MPP+) but not 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) selectively destroys dopaminergic neurons in cultures of dissociated rat mesencephalic neurons. Neurosci. Lett. 72, 215– 220. Sanchez-Ramos J., Hefti E., Hollinden D. E., Jasik T., and Rosenthal M. (1988) Mechanisms of neurotoxicity oxygen radicals and mitochondrial inhibition hypotheses, in Progress in Parkinson Research ( F. Hefti, ed), pp. 145– 152. Plenum Press, New York . Sayre L. M. (1989) Biochemical mechanism of action of the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydro-pyridine (MPTP). Toxicol. Lett. 48, 128– 149. Schapira A. H. V., Cooper J. M., Dexter D., Jenner P., Clark J. B., and Marsden C. D. (1989) Mitochondrial complex I deficiency in Parkinson's disease. J. Neurochem. 54, 823– 827. Schapira A. H. V., Mann V. M., Cooper J. M., Dexter D., Daniel S. E., Jenner P., Clark J. B., and Marsden C. D. (1990) Anatomic and disease specificity of NADH-CoQ1, reductase (complex I) deficiency in Parkinson's disease. J. Neurochem. 55, 2142– 2145. Schneider J. S., Yuwiler A., and Markham C. H. (1986) Production of a Parkinson-like syndrome in the cat with N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): behavior, histology and biochemistry. Exp. Neurol. 91, 293– 307. Schoenberg B. S., Osuntokun B. O., Adeuja A. O. G., Bademosi O., Nottidge V., Anderson D. W., and Haerer A. F. (1988) Comparison of the prevalence of Parkinson's disease in black populations of rural America and in rural Nigeria: door-to-door community studies. Neurology 38, 645– 646. Sen S. and D'lncalci M. (1992) Apoptosis: biochemical events and relation to cancer chemotherapy. FEBS Lett. 307, 122– 127. Singer C. and Weiner W. J. (1989) Could Parkinson's disease follow intra-uterine influenza? A speculative hypothesis. J. Neurol. Neurosurg. Psychiatry 52, 931– 937. Singer T. P. and Ramsay R. R. (1990) Mechanism of the neurotoxicity of MPTP: an update. FEBS Lett. 274, 1– 8. Singer T. P. and Ramsay R. R. (1991) The interaction of monoamine oxidases with tertiary amines. Biochem. Soc. Trans. 19, 211– 215. Singer T. P., Salach J. I., and Crabtree D. (1985) Reversible inhibition and mechanism-based inactivation of monoamine oxidase by 1-methyl-4-phenyl-l,2,3,6-tetrahydropyridine (MPTP). Biochem. Biophys. Res. Commun. 127, 707– 712. Singer T. P., Salach J. I., Castagnoli N., and Trevor A. J. (1986) Interactions of the neurotoxic amine 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine with monoamine oxidases. Biochem. J. 235, 785– 789. Singer T. P., Castagnoli N., Ramsay R. R., and Trevor A. J. (1987) Biochemical events in the development of Parkinson's disease induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. J. Neurochem. 49, 1– 8. Singer T. P., Ramsay R. R., Sonsalla P. K., Nicklas W. J., and Heikkila R. E. (1992) Biochemical mechanisms underlying MPTP-induced and idiopathic parkinsonism: new vistas, in Parkinson's Disease: From Basic Research to Treatment. ( H. Narabayashi, T. Nagatsu, N. Yanagisawa, and Y. Mizuno, eds), Raven Press, New York (in press). Snyder S. H. and D'Amato R. J. (1985) Predicting Parkinson's disease. Nature 317, 198. Snyder S. H. and D'Amato R. J. (1986) MPTP, a neurotoxin relevant to the pathophysiology of Parkinson's disease. Neurology 36, 250– 258. Sonsalla P. K. and Heikkila R. E. (1986) The influence of dose and dosing interval on MPTP-induced dopaminergic neurotoxicity in mice. Eur. J. Pharmacol. 129, 339– 345. Sonsalla P. K., Zeevalk G. D., Manzino L., Giovanni A., and Nicklas W. J. (1992) MK-801 fails to protect against the dopaminergic neuropathology produced by systemic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice or intranigral 1-methyl-4-phenylpyridinium in rats. J. Neurochem. 58, 1979– 1982. Steventon G. B., Heafield M. T. E., Waring R. H., and Williams A. C. (1989) Xenobiotic metabolism in Parkinson's disease. Neurology 39, 883– 887. Sullivan J. P. and Tipton K. F. (1988) Interactions of monoamine oxidase and MPTP in human brain, in Neurotoxins in Neurochemistry ( J. O. Dolly, ed), pp. 125– 131. Ellis Horwood, Chichester . Sullivan J. P. and Tipton K. F. (1990) The interactions of monoamine oxidase with some derivatives of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). J. Neural Transm. [Suppl.] 29, 269– 277. Sullivan J. P. and Tipton K. F. (1992) Interactions of the neurotoxin MPTP and its demethylated derivative (PTP) with monoamine oxidase-B. Neurochem. Res. 17, 791– 796. Sun C. J., Johannessen J. N., Gessner W., Namura I., Singhaniyom W., Brossi A., and Chiueh C. C. (1988) Neurotoxic damage to the nigrostriatal system in rats following intranigral administration of MPDP+ and MPP+. J. Neural Transm. 74, 75– 86. Suzuki K., Mizuno Y., and Yoshida M. (1988) Inhibition of mitochondrial NADH-ubiquinone oxidoreductase activity and ATP synthesis by tetrahydroisoquinoline. Neurosci. Lett. 86, 105– 108. Sziráki I., Kardos V., Patthy M., Pátfalusi M., Gaál J., Solti M., Kollár E., and Singer J. (1993) Amphetamine metabolites of deprenyl involved in protection against neurotoxicity induced by MPTP and 2′-methyl-MPTP. J. Neural Transm. (in press). Tanner C. M. (1989) The role of environmental toxins in the etiology of Parkinson's disease. Trends Neurosci. 12, 49– 54. Tasaki Y., Makino Y., Ohta S., and Hirobe M. (1991) 1-Methyl-1,2,3,4-tetrahydroisoquinoline, decreasing in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mouse, prevents parkinsonism-like behavior abnormalities. J. Neurochem. 57, 1940– 1943. Tatton W. G. and Greenwood C. E. (1991) Rescue of dying neurons: a new action of deprenyl in MPTP parkinsonism. J. Neurosci. Res. 30, 666– 672. Tatton W. G., Salo P. T., Greenwood C. E., Holland D. P., and Kwan M. M. (1992) Selegiline rescues dying neurons without causing MAO-B inhibition. Neurochem. Res. (in press). Tetrud J. W. and Langston J. W. (1989) The effect of deprenyl on the natural history of Parkinson's disease. Science 245, 519– 522. Tipton K. F. and Sullivan J. P. (1991) Biochemical aspects of the neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), in Probes for Neurochemical Target Sites ( K. F. Tipton and L. L. Iversen, eds), pp. 65– 71. Royal Irish Academy, Dublin . Tipton K. F., McCrodden J. M., and Youdim M. B. H. (1986) Oxidation and enzyme-activated irreversible inhibition of rat liver monoamine oxidase by 1-methyl-4-phenyl-1,2,3,6-tetra-hydropyridine. Biochem. J. 240, 379– 383. Turrens J. F. and Boveris A. (1980) Generation of superoxide anion by the NADH dehydrogenase of bovine heart mitochondria. Biochem. J. 191, 421– 427. Turski L., Bressler K., Rettig K.-J., Loschmann P. A., and Wachtel H. (1991) Protection of the substantia nigra from MPP+ neurotoxicity by N-methyl-D-aspartate antagonists. Nature 349, 414– 418. Ueki A., Chong P. N., Albanese A., Rose S., Chivers J. K., Jenner P., and Marsden C. D. (1989) Further treatment with MPTP does not produce parkinsonism in marmosets showing behavioural recovery from motor defects induced by an earlier exposure to the toxin. Neuropharmacology 28, 1089– 1097. Victoria J., Clark A., Machado A., and Satrusegui J. (1986) Impairment of glutamate uptake and absence of alterations in the energy transducing ability of old rat brain mitochondria. Mech. Ageing Dev. 29, 255– 266. Vyas I., Heikkila R. E., and Nicklas W. J. (1986) Studies on the neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: inhibition of NADH-linked substrate oxidation by its metabolite 1-methyl-4-phenylpyridinium. J. Neurochem. 46, 1501– 1507. Walker M. J., Jenner P., and Marsden C. D. (1991) A redox reaction between MPP+ and MPDP+ to produce superoxide radicals does not impair mitochondrial function. Biochem. Pharmacol. 42, 913– 919. Weissman J., Trevor A. J., Chiba K., Peterson L. A., Caldera P., and Castagnoli N. (1985) Metabolism of the nigrostriatal toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine by liver homogenate fractions. J. Med. Chem. 230, 997– 1001. Westlund K. M., Denney R. M., Kochersperger L. M., Rose R. M., and Abell C. W. (1985) Distinct MAO-A and B populations in primate brain. Science 230, 180– 182. Wu R.-M., Chiueh C. G., and Murphy D. L. (1993) Antioxidant effect of deprenyl on hydroxyl radical generation elicited by MPP+. Abstract of the FASEB Meeting, March 28-April 1, 1993 (in press). Yang S. C., Johannessen J. N. and Markey S. D. (1988) Metabolism of [14C]MPTP in mouse and monkey implicates MPP+, and not bound metabolites, as the operative toxin. Chem. Res. Toxicol. 1, 228– 233. Youdim M. B. H., Ben-Shachar D., and Riederer P. (1989) Is Parkinson's disease a progressive siderosis of substantia nigra resulting in iron and melanin induced neurodegeneration Acta Neurol. Scand. 126, 47– 54. Youngster S. K., Sonsalla P. K., and Heikkila R. E. (1987) Evaluation of the biological activity of several analogs of the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. J. Neurochem. 48, 929– 934. Youngster S. K., McKeown K. A., Jin Y.-Z., Ramsay R. R., Heikkila R. E., and Singer T. P. (1989) Oxidation of analogs of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine by monoamine oxidases A and B and the inhibition of monoamine oxidases by the oxidation products. J. Neurochem. 53, 1837– 1842. Citing Literature Volume61, Issue4October 1993Pages 1191-1206 ReferencesRelatedInformation